These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 28799237)
1. Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma. Liapis V; Zysk A; DeNichilo M; Zinonos I; Hay S; Panagopoulos V; Shoubridge A; Difelice C; Ponomarev V; Ingman W; Atkins GJ; Findlay DM; Zannettino ACW; Evdokiou A Cancer Med; 2017 Sep; 6(9):2164-2176. PubMed ID: 28799237 [TBL] [Abstract][Full Text] [Related]
2. Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models. Liapis V; Zinonos I; Labrinidis A; Hay S; Ponomarev V; Panagopoulos V; Zysk A; DeNichilo M; Ingman W; Atkins GJ; Findlay DM; Zannettino AC; Evdokiou A Cancer Med; 2016 Mar; 5(3):534-45. PubMed ID: 26749324 [TBL] [Abstract][Full Text] [Related]
3. Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma. Liapis V; Labrinidis A; Zinonos I; Hay S; Ponomarev V; Panagopoulos V; DeNichilo M; Ingman W; Atkins GJ; Findlay DM; Zannettino ACW; Evdokiou A Cancer Lett; 2015 Feb; 357(1):160-169. PubMed ID: 25444931 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo. Huang Y; Tian Y; Zhao Y; Xue C; Zhan J; Liu L; He X; Zhang L Cancer Commun (Lond); 2018 May; 38(1):15. PubMed ID: 29764490 [TBL] [Abstract][Full Text] [Related]
5. Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models. Sun JD; Liu Q; Ahluwalia D; Ferraro DJ; Wang Y; Jung D; Matteucci MD; Hart CP Cancer Biol Ther; 2016 Apr; 17(4):371-80. PubMed ID: 26818215 [TBL] [Abstract][Full Text] [Related]
6. Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models. Zhang L; Marrano P; Wu B; Kumar S; Thorner P; Baruchel S Clin Cancer Res; 2016 Jun; 22(11):2697-708. PubMed ID: 26719428 [TBL] [Abstract][Full Text] [Related]
7. Hypoxia-Activated Prodrug Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts Alters the Tumor Redox Status to Potentiate Radiotherapy. Kishimoto S; Brender JR; Chandramouli GVR; Saida Y; Yamamoto K; Mitchell JB; Krishna MC Antioxid Redox Signal; 2021 Oct; 35(11):904-915. PubMed ID: 32787454 [No Abstract] [Full Text] [Related]
8. Radiotherapy Synergizes with the Hypoxia-Activated Prodrug Evofosfamide: In Vitro and In Vivo Studies. Takakusagi Y; Kishimoto S; Naz S; Matsumoto S; Saito K; Hart CP; Mitchell JB; Krishna MC Antioxid Redox Signal; 2018 Jan; 28(2):131-140. PubMed ID: 28741367 [TBL] [Abstract][Full Text] [Related]
9. An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect. Hong CR; Wilson WR; Hicks KO Neoplasia; 2019 Feb; 21(2):159-171. PubMed ID: 30591421 [TBL] [Abstract][Full Text] [Related]
10. Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects. Hong CR; Dickson BD; Jaiswal JK; Pruijn FB; Hunter FW; Hay MP; Hicks KO; Wilson WR Biochem Pharmacol; 2018 Oct; 156():265-280. PubMed ID: 30134191 [TBL] [Abstract][Full Text] [Related]
11. Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer. Haynes J; McKee TD; Haller A; Wang Y; Leung C; Gendoo DMA; Lima-Fernandes E; Kreso A; Wolman R; Szentgyorgyi E; Vines DC; Haibe-Kains B; Wouters BG; Metser U; Jaffray DA; Smith M; O'Brien CA Clin Cancer Res; 2018 May; 24(9):2116-2127. PubMed ID: 29476017 [No Abstract] [Full Text] [Related]
12. The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy. Nytko KJ; Grgic I; Bender S; Ott J; Guckenberger M; Riesterer O; Pruschy M Oncotarget; 2017 Apr; 8(14):23702-23712. PubMed ID: 28423594 [TBL] [Abstract][Full Text] [Related]
13. A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients. Larue RT; Van De Voorde L; Berbée M; van Elmpt WJ; Dubois LJ; Panth KM; Peeters SG; Claessens A; Schreurs WM; Nap M; Warmerdam FA; Erdkamp FL; Sosef MN; Lambin P BMC Cancer; 2016 Aug; 16():644. PubMed ID: 27535748 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer. Sun JD; Liu Q; Ahluwalia D; Li W; Meng F; Wang Y; Bhupathi D; Ruprell AS; Hart CP Cancer Biol Ther; 2015; 16(3):438-49. PubMed ID: 25679067 [TBL] [Abstract][Full Text] [Related]
15. Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma. Jamieson SM; Tsai P; Kondratyev MK; Budhani P; Liu A; Senzer NN; Chiorean EG; Jalal SI; Nemunaitis JJ; Kee D; Shome A; Wong WW; Li D; Poonawala-Lohani N; Kakadia PM; Knowlton NS; Lynch CR; Hong CR; Lee TW; Grénman RA; Caporiccio L; McKee TD; Zaidi M; Butt S; Macann AM; McIvor NP; Chaplin JM; Hicks KO; Bohlander SK; Wouters BG; Hart CP; Print CG; Wilson WR; Curran MA; Hunter FW JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135316 [TBL] [Abstract][Full Text] [Related]
16. A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. Laubach JP; Liu CJ; Raje NS; Yee AJ; Armand P; Schlossman RL; Rosenblatt J; Hedlund J; Martin M; Reynolds C; Shain KH; Zackon I; Stampleman L; Henrick P; Rivotto B; Hornburg KTV; Dumke HJ; Chuma S; Savell A; Handisides DR; Kroll S; Anderson KC; Richardson PG; Ghobrial IM Clin Cancer Res; 2019 Jan; 25(2):478-486. PubMed ID: 30279233 [TBL] [Abstract][Full Text] [Related]
17. Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer. Yoon J; Kang SY; Lee KH; Cheon GJ; Oh DY Cancer Res Treat; 2021 Apr; 53(2):471-479. PubMed ID: 33091966 [TBL] [Abstract][Full Text] [Related]
18. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. Sun JD; Liu Q; Wang J; Ahluwalia D; Ferraro D; Wang Y; Duan JX; Ammons WS; Curd JG; Matteucci MD; Hart CP Clin Cancer Res; 2012 Feb; 18(3):758-70. PubMed ID: 22184053 [TBL] [Abstract][Full Text] [Related]
19. Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia. Badar T; Handisides DR; Benito JM; Richie MA; Borthakur G; Jabbour E; Harutyunyan K; Konoplev S; Faderl S; Kroll S; Andreeff M; Pearce T; Kantarjian HM; Cortes JE; Thomas DA; Konopleva M Am J Hematol; 2016 Aug; 91(8):800-5. PubMed ID: 27169385 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302. Li S; Zhang J; Li J; Chen D; Matteucci M; Curd J; Duan JX Biol Trace Elem Res; 2010 Sep; 136(3):294-301. PubMed ID: 19838642 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]